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incidence
The incidence of malignant glioma is 5/100 000. Malignant
glioma may develop at all ages, the peak incidence being in
the fifth and sixth decades of life.
diagnosis
Malignant glioma comprises glioblastoma [World Health
Organization (WHO) grade IV], anaplastic astrocytoma
(WHO grade III), mixed anaplastic oligoastrocytoma
(WHO grade III) and anaplastic oligodendroglioma (WHO
grade III). Diagnosis after biopsy or tumour resection is
made according to the revised WHO classification. Prognosis
depends on tumour grade and histology. Glioblastoma carries
the worst prognosis, while pure oligodendroglioma tends to
have the best outcome and higher response rates to both
chemotherapy and radiation. Prognosis of mixed anaplastic
oligoastrocytoma and anaplastic astrocytoma is intermediate
between glioblastoma and pure anaplastic oligodendroglioma.
Concordance between local diagnosis and central
neuropathology review can be as low as 50%, thus careful
review of the histology is recommended.
Primary brain tumours only very rarely disseminate
outside the central nervous system, thus no systemic staging is
required except for differential diagnosis of brain metastasis.
molecular markers
Genetic loss on chromosomes 1p/19q (LOH 1p/19q), recently
recognized as a chromosomal translocation has been advocated
as a marker for responsiveness to chemotherapy. However, it
describes a distinct tumour entity with a prolonged natural
history irrespective of treatment. LOH 1p/19q should be
performed to support a diagnosis of oligodendroglioma.
Epigenetic silencing of the methyl-guanine methyl transferase
(MGMT) gene promoter by methylation suggests a partial
inability of the tumour to repair the chemotherapy-induced
DNA damage. In retrospective analyses it has been correlated
with outcome to alkylating agent chemotherapy [II, B]. MGMT
determination by immunohistochemistry has been suggested;
however, this method lacks standardization, reproducibility
and correlation with clinical outcome [III, C]. Short of
established alternative treatments and in the absence of clinical
consequences routine determination of the MGMT promoter
methylation status does not (yet) add to the patient
management outside clinical trials [V, D]
staging and risk assessment
Staging includes imaging of the brain, ideally by magnetic
resonance (MRI). Extent of resection and determination of
residual disease should be assessed within 24–48 h after surgery
[III, B]. Lumbar puncture is generally not useful, and staging
of other organs is not needed. Lower tumour grade, radical
tumour resection, younger age (<50 years), good performance
status and an intact neurological function, have been
identified as more favourable prognostic factors.
treatment plan
Patients should be evaluated by a specialized multidisciplinary
team. Special consideration needs to be given to performance
status and neurological function. High doses of corticosteroids
(usually dexamethasone 8–16 mg/day) allow rapid reduction
of tumour-associated oedema and improve clinical symptoms;
corticosteroid dose should then be rapidly tapered according
to individual needs. The patient’s glucose levels need to be
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monitored. Steroids are not necessary in patients without
increased intracranial pressure and absence of neurological
deficits. There is no need for prolonged steroid therapy after
tumour resection or prophylaxis during radiotherapy.
Antiepileptic therapy is indicated in patients presenting with
an initial seizure; however, prophylactic antiepileptic therapy
before or after surgery is not needed [III, C]. After tumour
resection, the indication for anti-seizure therapy should be
revisited. First-generation antiepileptic drugs (phenytoin,
carbamazepine, phenobarbital and their derivates) are strong
inducers of the hepatic metabolism, and may interfere with
medications including many commonly used chemotherapy
agents (but not with temozolomide). Third-generation agents
such as lamotrigine, levetiracetam or pregabalin are preferred.
newly diagnosed patients
surgery. Surgery is commonly the initial therapeutic approach
for tumour debulking and obtaining tissue for diagnosis.
Tumour resection is of prognostic value; it may be beneficial
to attempt maximal tumour resection provided that
neurological function is not compromised by the extent of
resection [II, C]. When microsurgical resection is not safely
feasible (e.g. due to location of the tumour or impaired clinical
condition of the patient), a stereotactic serial biopsy should be
performed. The diagnostic yield is >95% in experienced hands,
moreover molecular genetic analyses (LOH 1p/19q, MGMT
promoter methylation) can be performed on freshly frozen
specimens. Implantation of chemotherapy-impregnated wafers
(carmustine polymers) into the resection cavity before
radiotherapy has been shown to marginally improve median
survival compared with radiotherapy alone in patients who
have radical tumour resection [II, B]. However, subgroup
analysis did not show significant benefit for patients with
glioblastoma. No data are available when compared with
standard temozolomide/radiotherapy (TMZ/RT, see below)
and there is no information about potential additive value.
radiotherapy. Fractionated focal radiotherapy (60 Gy, 30–33
fractions of 1.8–2 Gy, or equivalent doses/fractionations) is
the standard treatment after resection or biopsy [I, A].
Escalating doses beyond 60 Gy has not been shown to be of
value. In elderly patients or patients with poor performance
status, shorter hypofractionated regimens (e.g. 40 Gy in 15
fractions) are commonly proposed [II, B]. Radiotherapy
(28·1.8 Gy, 50 Gy) in patients >70 years of age was superior to
best supportive care alone in a randomized phase III trial
[II, B].
chemotherapy. Exclusive chemotherapy (usually TMZ) has been
proposed for elderly patients, randomized data will be
presented at the American Society of Clinical Oncology Annual
Meeting in June 2010. For glioblastoma, concomitant
chemoradiotherapy is the standard of care. TMZ (at a low
dose of 75 mg/m2) is administered daily (7 days/week)
1–1.5 hours before radiotherapy from the first to the last
day of radiotherapy (usually 40–49 days). Continuous daily
administration of TMZ will induce profound lymphocytopenia
with CD4 counts <200/mm3 and this is associated with an
increased risk of opportunistic Pneumocystis pneumonia.
Similarly, steroids will also lower the lymphocyte counts.
Prophylactic administration of pentamidine inhalations or
trimethoprim–sulfamethoxazole during concomitant
chemoradiotherapy should be considered, but is not required
during the adjuvant daily ·5 TMZ administration. The
blood counts should be monitored weekly, and chemotherapy
should be temporarily suspended in the case of
thrombocytes <75.000/mm3 or a neutrophil count of <1500/
mm3. During the maintenance phase TMZ (150–200 mg/m2) is
administered on a daily ·5 schedule every 28 days; blood
counts should be checked on days 21 and 28.
glioblastoma (WHO grade IV)
Concomitant and adjuvant TMZ chemotherapy significantly
improved median, 2- and 5-year survival in a large randomized
trial, and is the current standard of care for patients with
glioblastoma up to age 70 [I, A]. No randomized data are
available for elderly patients (>70 years) with a good
performance status. TMZ is administered daily during
radiotherapy, and for 5 days every 4 weeks for six cycles as
maintenance (adjuvant) treatment after the end of radiation.
Selecting patients likely to benefit from therapy on the basis
of MGMT gene promoter methylation has been suggested
[II, B], and prospective validation studies have completed
accrual. Adjuvant chemotherapy with procarbazine, lomustine
and vincristine (PCV regimen) has failed to improve survival
in individual prospective randomized studies, both in grade IV
and in grade III tumours [I, A]. Nevertheless, based on
a large meta-analysis [I, A] nitrosourea-based chemotherapy
marginally improves survival.
anaplastic astrocytoma, oligoastrocytoma and
oligodendroglioma (WHO grade III)
Anaplastic astrocytoma and oligoastrocytoma have a more
protracted clinical course. Standard therapy consists of
adjuvant radiotherapy up to 60 Gy after surgery. The value
of concomitant and/or maintenance chemotherapy with TMZ
has not yet been tested prospectively [V, D]. Randomized
clinical trials did not demonstrate prolonged survival with
(neo-)adjuvant PCV chemotherapy [procarbazine, lomustine
(CCNU)] in newly diagnosed anaplastic oligoastrocytoma and
oligodendroglioma [I, B], although progression-free survival
was prolonged. Oligodendroglioma characterized by LOH
1p/19q has a more favourable natural history. Early
administration of adjuvant chemotherapy before or after
radiation did not impact overall survival, despite the exquisite
chemo-responsiveness [II, B]. Time to failure of both
chemotherapy and radiation was similar whether patients were
initially treated with chemotherapy (and receiving RT at first
progression) or being treated with initial RT (and
administration of chemotherapy at progression) in
a randomized trial [II, B]. No difference in efficacy was
apparent between PCV and TMZ chemotherapy [III, B].
recurrent disease
Some benefit of chemotherapy has been shown for patients
with an adequate performance status who have not received
prior adjuvant cytotoxic therapy. Anaplastic astrocytomas are
more likely than glioblastoma to respond to TMZ
chemotherapy [III, B]. For patients progressing after prior
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chemotherapy, there is no established chemotherapy regimen
available and patients are best treated within investigational
clinical protocols. Single-agent nitrosourea therapy may achieve
tumour control in some patients, while randomized trials
have failed to demonstrate measurable antitumour efficacy of
epidermal growth factor receptor (EGFR) inhibition by
erlotinib or platelet-derived growth factor receptor (PDGFR)
inhibition by imatinib in an unselected patient population
[II, C]. High imaging response rates and a steroid-sparing effect
have been observed with administration of bevacizumab
(6 irinotecan). However, the effect is frequently short lived and
may be largely due to changes in vascular permeability. The
effect on life expectancy remains unknown [III, C]. On the
basis of the available evidence bevacizumab is not currently
approved by the European Medicines Agency for recurrent
glioblastoma. The indication for re-operation should be
evaluated [IV, C]; insertion of chemotherapy-impregnated
polymers following repeat radical surgery leads to marginal
prolongation of survival in selected patients [II, B].
response evaluation
MRI is the preferred imaging method. Contrast enhancement
and presumed tumour progression on imaging 4–8 weeks after
the end of radiotherapy may be due to a reactive process
following radiotherapy (pseudoprogression) or may be due to
true progression and this should be re-evaluated 4–8 weeks
later with a second MRI. Apparent increase in tumour size after
the end of radiotherapy should not lead to discontinuation
of chemotherapy. Response to chemotherapy is evaluated
according to the WHO criteria, but should also include an
assessment of neurological function and corticosteroid use
(Macdonald criteria). The recent introduction of
antiangiogenic and vasculature-modifying agents warrants
reassessment of response criteria. In addition to contrast
enhancement, tumour extension on T2- and fluid-attenuated
inversion recovery (FLAIR)-weighted MRI needs to be
evaluated. In cases of doubtful differential diagnosis between
tumour recurrence and treatment-induced changes (especially
after multimodal therapy), positron-emission tomography
(PET) with an amino acid tracer (e.g. methionine, fluoro-
ethyltyrosine) may be helpful [III, B].
follow-up
Follow-up consists of a clinical evaluation with particular
attention to neurological function, seizures and corticosteroid
use. Patients should be tapered off steroid use as early as
possible. Venous thrombotic events occur frequently in patients
with residual or recurrent tumours. Laboratory tests are not
indicated unless the patient is receiving chemotherapy (blood
counts), corticosteroids (glucose) or antiepileptic drugs (blood
count, liver function tests). MRI every 3–4 months is standard
practice outside clinical trials, unless more frequent monitoring
is clinically indicated.
note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
literature
1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:
492–507.
2. Louis D, Ohgaki H, Wiestler O, Cavenee WK. WHO Classification of Tumours of
the Central Nervous System. Lyon: International Agency for Research on Cancer
2007.
3. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl
J Med 2009; 360: 765–773.
4. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant
glioma: standard of care and future directions. J Clin Oncol 2007; 25:
4127–4136.
5. Stupp R, Hottinger AF, van den Bent MJ et al. Frequently asked questions in the
medical management of high-grade glioma: a short guide with practical
answers. ESMO Educational Book. Ann Oncol 2008; 19 (Suppl 7): vii209–
vii216.
6. Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance
imaging after resection of malignant glioma: objective evaluation of residual
tumor and its influence on regrowth and prognosis. Neurosurgery 1994; 34:
45–60.
7.0 Stummer W, Pichlmeier U, Meinel T et al. Fluorescence-guided surgery with
5aminolevulinic acid for resection of malignant glioma: a randomised controlled
multicentre phase III trial. Lancet Oncol 2006; 7: 392–401.
8. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients
with glioblastoma multiforme: prognosis, extent of resection, and survival.
J Neurosurg 2001; 95: 190–198.
9. Westphal M, Ram Z, Riddle V et al. Gliadel wafer in initial surgery for malignant
glioma: longterm follow-up of a multicenter controlled trial. Acta Neurochir (Wien)
2006; 148: 269–275.
10. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and
meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;
359: 1011–1018.
11. Medical Research Council Brain Tumor Working Party. Randomized trial of
procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade
astrocytoma. Medical Research Council trial. J Clin Oncol 2001; 19: 509–518.
12. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in
older patients with glioblastoma multiforme: a prospective randomized clinical
trial. J Clin Oncol 2004; 22: 1583–1588.
13. Stupp R, Mason WP, van den Bent MJ et al. Concomitant and adjuvant
temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme.
N Engl J Med 2005; 352: 987–996.
14. Stupp R, Hegi ME, Mason WP et al. on behalf of the European Organisation for
Research and Treatment of Cancer Brain Tumour and Radiation Oncology
Groups and the National Cancer Institute of Canada Clinical Trials Group. Effects
of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy
alone on survival in glioblastoma in a randomised phase III study: 5-year analysis
of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–66.
15. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from
temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003.
16. Weller M, Stupp R, Reifenberger G et al. MGMT promoter methylation in
malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010; 6:
39–51.
17. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in
the elderly. N Engl J Med 2007; 356: 1527–1535.
18. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status
can predict the incidence and outcome of pseudoprogression after concomitant
radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;
26: 2192–2197.
19. Brandsma D, Stalpers L, Taal W et al. Clinical features, mechanisms, and
management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9:
453–461.
clinical practice guidelines Annals of Oncology
v192 | Stupp et al. Volume 21 | Supplement 5 |May 2010
20. van den Bent MJ, Vogelbaum MA, Wen PY et al. End point assessment in
gliomas: novel treatments limit usefulness of classical Macdonald’s Criteria.
J Clin Oncol 2009; 27: 2905–2908.
21. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant
procarbazine, lomustine, and vincristine improves progression-free
survival but not overall survival in newly diagnosed anaplastic
oligodendrogliomas and oligoastrocytomas: A randomized European
Organization for Research and Treatment of Cancer phase III trial. J Clin
Oncol 2006; 24: 2715–2722.
22. Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus
radiotherapy compared with radiotherapy alone for pure and mixed anaplastic
oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
J Clin Oncol 2006; 24: 2707–2714.
23. Wick W, Hartmann C, Engel C et al. NOA-04 randomized phase III trial of
sequential radiochemotherapy of anaplastic glioma with procarbazine,
lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27:
5874–5880.
24. van den Bent MJ, Dubbink HJ, Sanson M. MGMT promoter methylation is
prognostic but not predictive for outcome to adjuvant PCV chemotherapy in
anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group
Study 26951. J Clin Oncol 2009; 27: 5881–5886.
25. Jaeckle KA, Ballman KV, Rao RD et al. Current strategies in treatment of
oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol
2006; 24: 1246–1252.
26. van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-
line chemotherapy with temozolomide in recurrent oligodendroglial
tumors: the European Organization for Research and Treatment of
Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21:
2525–2528.
27. van den Bent MJ, Brandes AA, Rampling R et al. Randomized phase II trial of
erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC
brain tumor group study 26034. J Clin Oncol 2009; 27: 1268–1274.
28. Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients
with recurrent gliomas of various histologies: a European Organisation for
Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008;
26: 4659–4665.
29. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab
followed by bevacizumab plus irinotecan at tumor progression in recurrent
glioblastoma. J Clin Oncol 2009; 27: 740–745.
30. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination
with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733–4740.
31. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant
gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70:
779–787.
32. Wick W, Weller M, van den Bent MJ, Stupp R. Avastin and recurrent glioma.
A European perspective. J Clin Oncol 2010; 28: e188–e189.
33. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for
phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:
1277–1280.
34. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in
recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;
17: 2572–2578.
35. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in
malignant gliomas: a computed tomographic scan study by the Brain Tumor
Cooperative Group. J Clin Oncol 1988; 6: 338–343.
36. Rachinger W, Goetz C, Po¨pperl G et al. Positron emission tomography with O-(2-
[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis
of recurrent gliomas. Neurosurgery 2005; 57: 505–511.
Annals of Oncology clinical practice guidelines
Volume 21 | Supplement 5 |May 2010 doi:10.1093/annonc/mdq187 | v193
